<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 3.5d -->
    <!-- Field: Doc-Info; Name: Source; Value: IMMY 063013_q2.xfr; Date: 2013/08/14T18:43:25 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://imprimispharma.com/role/DocumentAndEntityInformation" xlink:href="immy-20130630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CondensedConsolidatedBalanceSheets" xlink:href="immy-20130630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="immy-20130630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:href="immy-20130630.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="immy-20130630.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/OverviewAndBasisOfPresentation" xlink:href="immy-20130630.xsd#OverviewAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Short-TermRestictedInvestment" xlink:href="immy-20130630.xsd#Short-TermRestictedInvestment" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses" xlink:href="immy-20130630.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensation" xlink:href="immy-20130630.xsd#StockholdersEquityAndStock-BasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies" xlink:href="immy-20130630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SubsequentEvents" xlink:href="immy-20130630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/OverviewAndBasisOfPresentationPolicies" xlink:href="immy-20130630.xsd#OverviewAndBasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/OverviewAndBasisOfPresentationTables" xlink:href="immy-20130630.xsd#OverviewAndBasisOfPresentationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="immy-20130630.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityAndStockBasedCompensationTables" xlink:href="immy-20130630.xsd#StockholdersEquityAndStockBasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/OverviewAndBasisOfPresentationDetails" xlink:href="immy-20130630.xsd#OverviewAndBasisOfPresentationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/OverviewAndBasisOfPresentationDetails1" xlink:href="immy-20130630.xsd#OverviewAndBasisOfPresentationDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/OverviewAndBasisOfPresentationDetailsNarrative" xlink:href="immy-20130630.xsd#OverviewAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Short-TermRestictedInvestmentDetailsNarrative" xlink:href="immy-20130630.xsd#Short-TermRestictedInvestmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:href="immy-20130630.xsd#AccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:href="immy-20130630.xsd#AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails" xlink:href="immy-20130630.xsd#StockholdersEquityAndStock-BasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails1" xlink:href="immy-20130630.xsd#StockholdersEquityAndStock-BasedCompensationDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails2" xlink:href="immy-20130630.xsd#StockholdersEquityAndStock-BasedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityAndStockBasedCompensationDetails3" xlink:href="immy-20130630.xsd#StockholdersEquityAndStockBasedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails4" xlink:href="immy-20130630.xsd#StockholdersEquityAndStock-BasedCompensationDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails5" xlink:href="immy-20130630.xsd#StockholdersEquityAndStock-BasedCompensationDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails6" xlink:href="immy-20130630.xsd#StockholdersEquityAndStock-BasedCompensationDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails7" xlink:href="immy-20130630.xsd#StockholdersEquityAndStock-BasedCompensationDetails7" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityAndStockBasedCompensationDetailsNarrative" xlink:href="immy-20130630.xsd#StockholdersEquityAndStockBasedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="immy-20130630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/DocumentAndEntityInformation" xlink:title="0001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CondensedConsolidatedBalanceSheets" xlink:title="0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaapRestrictedCashAndInvestmentsCurrent" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashAndInvestmentsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaapDevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapDevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:title="0004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaapLicensesRevenue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapLicensesRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaapGainLossRelatedToLitigationSettlement" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_us-gaapGainLossRelatedToLitigationSettlement" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="immy-20130630.xsd#IMMY_GainOnForgivenessOfLiabilities" xlink:label="loc_IMMYGainOnForgivenessOfLiabilities" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingExpense" xlink:to="loc_IMMYGainOnForgivenessOfLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:title="0005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20130630.xsd#IMMY_EstimatedFairValueOfContributedServices" xlink:label="loc_IMMYEstimatedFairValueOfContributedServices" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMMYEstimatedFairValueOfContributedServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20130630.xsd#IMMY_GainOnForgivenessOfLiabilities" xlink:label="loc_IMMYGainOnForgivenessOfLiabilities" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMMYGainOnForgivenessOfLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="immy-20130630.xsd#IMMY_AmortizationOfPrepaidConsultingFees" xlink:label="loc_IMMYAmortizationOfPrepaidConsultingFees" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMMYAmortizationOfPrepaidConsultingFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20130630.xsd#IMMY_PrepaidConsultingCosts" xlink:label="loc_IMMYPrepaidConsultingCosts" />
      <link:calculationArc order="1000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMMYPrepaidConsultingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="1100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="1200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="1300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="1400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="1500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaapProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="immy-20130630.xsd#IMMY_PaymentForSettlementOfSharesInConnectionWithReverseStockSplit" xlink:label="loc_IMMYPaymentForSettlementOfSharesInConnectionWithReverseStockSplit" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_IMMYPaymentForSettlementOfSharesInConnectionWithReverseStockSplit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="immy-20130630.xsd#IMMY_ProceedsFromIssuanceOfNotesPayableToStockholders" xlink:label="loc_IMMYProceedsFromIssuanceOfNotesPayableToStockholders" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_IMMYProceedsFromIssuanceOfNotesPayableToStockholders" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20130630.xsd#IMMY_ProceedsReceivedInConnectionWithDebtModification" xlink:label="loc_IMMYProceedsReceivedInConnectionWithDebtModification" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_IMMYProceedsReceivedInConnectionWithDebtModification" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaapProceedsFromContributedCapital" />
      <link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromContributedCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20130630.xsd#IMMY_PreferredStockDeemedDividendPaidAtConversion" xlink:label="loc_IMMYPreferredStockDeemedDividendPaidAtConversion" />
      <link:calculationArc order="1100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_IMMYPreferredStockDeemedDividendPaidAtConversion" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/OverviewAndBasisOfPresentation" xlink:title="0006 - Disclosure - 1. OVERVIEW AND BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Short-TermRestictedInvestment" xlink:title="0007 - Disclosure - 2. SHORT-TERM RESTICTED INVESTMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses" xlink:title="0008 - Disclosure - 3. ACCOUNTS PAYABLE AND ACCRUED EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensation" xlink:title="0009 - Disclosure - 4. STOCKHOLDERS' EQUITY AND STOCK- BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingencies" xlink:title="0010 - Disclosure - 5. COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SubsequentEvents" xlink:title="0011 - Disclosure - 6. SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/OverviewAndBasisOfPresentationPolicies" xlink:title="0012 - Disclosure - OVERVIEW AND BASIS OF PRESENTATION (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/OverviewAndBasisOfPresentationTables" xlink:title="0013 - Disclosure - OVERVIEW AND BASIS OF PRESENTATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="0014 - Disclosure - 3. ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityAndStockBasedCompensationTables" xlink:title="0015 - Disclosure - 4. STOCKHOLDERS EQUITY AND STOCK BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/OverviewAndBasisOfPresentationDetails" xlink:title="0016 - Disclosure - 1. OVERVIEW AND BASIS OF PRESENTATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/OverviewAndBasisOfPresentationDetails1" xlink:title="0017 - Disclosure - 1. OVERVIEW AND BASIS OF PRESENTATION (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/OverviewAndBasisOfPresentationDetailsNarrative" xlink:title="0018 - Disclosure - 1. OVERVIEW AND BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Short-TermRestictedInvestmentDetailsNarrative" xlink:title="0019 - Disclosure - 2. SHORT-TERM RESTICTED INVESTMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:title="0020 - Disclosure - 3. ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:title="0021 - Disclosure - 3. ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails" xlink:title="0022 - Disclosure - 4. STOCKHOLDERS EQUITY AND STOCK - BASED COMPENSATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails1" xlink:title="0023 - Disclosure - 4. STOCKHOLDERS EQUITY AND STOCK - BASED COMPENSATION (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails2" xlink:title="0024 - Disclosure - 4. STOCKHOLDERS EQUITY AND STOCK - BASED COMPENSATION (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityAndStockBasedCompensationDetails3" xlink:title="0025 - Disclosure - 4. STOCKHOLDERS EQUITY AND STOCK BASED COMPENSATION (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails4" xlink:title="0026 - Disclosure - 4. STOCKHOLDERS EQUITY AND STOCK - BASED COMPENSATION (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails5" xlink:title="0027 - Disclosure - 4. STOCKHOLDERS' EQUITY AND STOCK- BASED COMPENSATION (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails6" xlink:title="0028 - Disclosure - 4. STOCKHOLDERS' EQUITY AND STOCK- BASED COMPENSATION (Details 6)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityAndStock-BasedCompensationDetails7" xlink:title="0029 - Disclosure - 4. STOCKHOLDERS' EQUITY AND STOCK- BASED COMPENSATION (Details 7)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityAndStockBasedCompensationDetailsNarrative" xlink:title="0030 - Disclosure - 4. STOCKHOLDERS EQUITY AND STOCK BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="0031 - Disclosure - 5. COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
</link:linkbase>
